JP2024508709A5 - - Google Patents

Info

Publication number
JP2024508709A5
JP2024508709A5 JP2023548578A JP2023548578A JP2024508709A5 JP 2024508709 A5 JP2024508709 A5 JP 2024508709A5 JP 2023548578 A JP2023548578 A JP 2023548578A JP 2023548578 A JP2023548578 A JP 2023548578A JP 2024508709 A5 JP2024508709 A5 JP 2024508709A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody according
chain
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508709A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016683 external-priority patent/WO2022178047A1/en
Publication of JP2024508709A publication Critical patent/JP2024508709A/ja
Publication of JP2024508709A5 publication Critical patent/JP2024508709A5/ja
Pending legal-status Critical Current

Links

JP2023548578A 2021-02-17 2022-02-17 抗cd123結合分子及びその使用法 Pending JP2024508709A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163150488P 2021-02-17 2021-02-17
US63/150,488 2021-02-17
US202163249455P 2021-09-28 2021-09-28
US63/249,455 2021-09-28
PCT/US2022/016683 WO2022178047A1 (en) 2021-02-17 2022-02-17 Anti-cd123 binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2024508709A JP2024508709A (ja) 2024-02-28
JP2024508709A5 true JP2024508709A5 (cg-RX-API-DMAC7.html) 2025-02-21

Family

ID=82931699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548578A Pending JP2024508709A (ja) 2021-02-17 2022-02-17 抗cd123結合分子及びその使用法

Country Status (9)

Country Link
US (1) US20240076392A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294829A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024508709A (cg-RX-API-DMAC7.html)
KR (1) KR20230146022A (cg-RX-API-DMAC7.html)
AU (1) AU2022221633A1 (cg-RX-API-DMAC7.html)
CA (1) CA3205834A1 (cg-RX-API-DMAC7.html)
IL (1) IL304485A (cg-RX-API-DMAC7.html)
MX (1) MX2023009615A (cg-RX-API-DMAC7.html)
WO (1) WO2022178047A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130635A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
KR102357312B1 (ko) * 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
EP3515491A4 (en) * 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
US11840569B2 (en) * 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
CA3055790A1 (en) * 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
EP3630839A1 (en) * 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
AU2019343184B2 (en) * 2018-09-20 2026-04-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
CN114040926B (zh) * 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
JP7585305B2 (ja) * 2019-08-17 2024-11-18 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体の二重特異性抗cd123結合分子及びその使用

Similar Documents

Publication Publication Date Title
JP7411316B2 (ja) 三重特異性結合タンパク質と使用方法
JP2020063262A5 (cg-RX-API-DMAC7.html)
RU2558301C2 (ru) Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
JP2021502810A5 (cg-RX-API-DMAC7.html)
JP2022545655A5 (cg-RX-API-DMAC7.html)
JP2019196365A5 (cg-RX-API-DMAC7.html)
CN111423512B (zh) 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2020508068A5 (cg-RX-API-DMAC7.html)
KR20200123782A (ko) 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도
JP2013527761A5 (cg-RX-API-DMAC7.html)
JP6242484B2 (ja) 特定の改善されたヒト二重特異性EGFRvIII抗体結合分子
TWI916327B (zh) 結合pd-1的抗體
JP2018504092A5 (cg-RX-API-DMAC7.html)
JP2007532139A5 (cg-RX-API-DMAC7.html)
AR039067A1 (es) Anticuerpos para cd40
JP2020521478A5 (cg-RX-API-DMAC7.html)
KR20230130148A (ko) Cd20 결합 분자 및 그의 용도
RU2013134983A (ru) Рекомбинантные антитела против фактора роста эндотелия сосудов (vegf), полученные посредством мутагенеза вариабельной области
JP2023544143A5 (cg-RX-API-DMAC7.html)
JP7738914B2 (ja) TriAx抗体の組成、その製造方法及び使用方法
JP2025128343A5 (cg-RX-API-DMAC7.html)
JP2010500006A5 (cg-RX-API-DMAC7.html)
KR20230141817A (ko) 이중특이 항체
JP2025506341A5 (cg-RX-API-DMAC7.html)